Genomic landscape of myelodysplastic/myeloproliferative neoplasm can predict response to hypomethylating agent therapy-Reference-Cited by-同舟云学术

Genomic landscape of myelodysplastic/myeloproliferative neoplasm can predict response to hypomethylating agent therapy

Published:2022-04-04 Issue:8 Volume:63 Page:1942-1948
ISSN:1042-8194
Container-title:Leukemia & Lymphoma
language:en
Short-container-title:Leukemia & Lymphoma

Author:

Karantanos Theodoros¹,Tsai Hua-Ling²,Gondek Lukasz P.¹,DeZern Amy E.¹,Ghiaur Gabriel¹,Dalton W. Brian¹^ORCID,Gojo Ivana¹,Prince Gabrielle T.¹,Webster Jonathan¹^ORCID,Ambinder Alexander¹,Smith B. Douglas¹,Levis Mark J.¹,Varadhan Ravi²,Jones Richard J.¹,Jain Tania¹^ORCID

Affiliation:

1. Division of Hematological Malignancies and Bone Marrow Transplantation, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, MD, USA

2. Division of Biostatistics and Bioinformatics, Johns Hopkins/Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD, USA

Funder

NIH/NHLBI

Publisher

Informa UK Limited

Subject

Cancer Research,Oncology,Hematology

Link

https://www.tandfonline.com/doi/pdf/10.1080/10428194.2022.2057488

Reference28 articles.

1. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia

2. Molecular landscape and clonal architecture of adult myelodysplastic/myeloproliferative neoplasms